

Sarcoma de Kaposi

Daunorrubicina lipossomal

Daunorrubicina lipossomal: 40 mg/m² IV D1

a cada 14 dias

Ref. (1)

Doxorrubicina lipossomal peguilada

Doxorrubicina lipossomal peguilada: 20 mg/m² IV D1

a cada 21 dias

Ref. (2)

Paclitaxel

Paclitaxel: 135 mg/m² IV durante 3 horas D1

a cada 21 dias

Ref. (3)

OU

Paclitaxel: 100 mg/m² IV durante 3 horas D1

a cada 14 dias

ABV

Doxorrubicina: 20 mg/m² IV D1

Bleomicina: 10 mg/m² IV D1

Vincristina: 1 mg IV D1 a cada 14 dias

Ref. (4)

1. Gill PS, *et al.* Randomizes phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS- related Kaposi's sarcoma. *J Clin Oncol* 1996;14:2353-2364.

2. Northfelt DW, *et al.* Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS related Kaposi's sarcoma after failure of standard chemotherapy. *J Clin Oncol* 1997;15:653-659.
3. Gill PS, *et al.* Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. *J Clin Oncol* 1999;17:1876-1880.
Gill PS, *et al.* Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi's sarcoma. *Cancer* 2002;95:147-154.
4. Northfelt DW, *et al.* *J Clin Oncol* 1998;16:2445-51.